Eli Lilly's new weight-loss drug crushes trials — ride the obesity drug wave
Thesis
The weight-loss drug market is turning into a gold rush, and Eli Lilly just proved they have the next big product ready to capture market share. With analysts confirming that the company's pipeline has multiple potential blockbusters rather than just one, this stock has fundamental staying power beyond a single day's pop. As the broader market looks for strong companies to invest in amid tech volatility, healthcare leaders with breakthrough drugs offer a safe harbor with massive growth potential. Rival companies like Novo Nordisk could also ride the coattails of this renewed industry excitement.
Strategy approach
Build a long breakout strategy for LLY on the daily timeframe. Entry: Price breaks and closes above the highest high of the last 10 trading days. Exit: Price fails to close above the 10-day exponential moving average for two consecutive days. Risk management: 4% fixed stop loss from entry price.